A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by science, but by financial viability. As Kristen Hege, former SVP at Bristol Myers Squibb, explains:“Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s […]
